A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naive HIV-1-infected Participants
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 14 Dec 2017 24 week results published in the Clinical Infectious Diseases.
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science.